KURA
Kura Oncology, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.35
P/S
11.27
EV/EBITDA
-2.18
DCF Value
$23.41
FCF Yield
-9.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.6%
Operating Margin
-449.9%
Net Margin
-412.9%
ROE
-102.6%
ROA
-37.7%
ROIC
-48.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $17.3M | $-81.0M | $-0.92 |
| FY 2025 | $67.5M | $-278.7M | $-3.18 |
| Q3 2025 | $20.8M | $-74.1M | $-0.85 |
| Q2 2025 | $15.3M | $-66.1M | $-0.75 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.24
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.